TY - JOUR
T1 - Oxycodone initiation in Australia (2014–2018)
T2 - Sociodemographic factors and preceding health service use
AU - Gillies, Malcolm B.
AU - Camacho, Ximena
AU - Bharat, Chrianna
AU - Buizen, Luke
AU - Blyth, Fiona
AU - Currow, David
AU - Wilson, Andrew
AU - Degenhardt, Louisa
AU - Gisev, Natasa
AU - Pearson, Sallie-Anne
PY - 2024/7
Y1 - 2024/7
N2 - Aims: Oxycodone is the most commonly prescribed strong opioid in Australia. This study describes health service antecedents and sociodemographic factors associated with oxycodone initiation. Methods: Population-based new user cohort study linking medicine dispensings, hospitalizations, emergency department visits, medical services and cancer notifications from New South Wales (NSW) for 2014–2018. New users had no dispensings of any opioid in the preceding year. We analysed health service use in the 5 days preceding initiation and proportion of people on treatment over 1 year and fitted an area-based, multivariable initiation model with sociodemographic covariates. Results: Oxycodone accounted for 30% of opioid initiations. Annually, 3% of the NSW population initiated oxycodone, and 5–6% were prevalent users; the new user cohort comprised 830 963 people. Discharge from hospital (39.3%), therapeutic procedures (21.4%) and emergency department visits (19.7%) were common; a hospital admission for injury (6.0%) or a past-year history of cancer (7.2%) were less common. At 1 year after initiation, 4.6% of people were using oxycodone. In the multivariable model, new use of oxycodone increased with age and was higher for people outside major cities, for example, an incidence rate ratio of 1.43 (95% confidence interval 1.36–1.51) for inner regional areas relative to major cities; there was no evidence of variation in rates of new use by social disadvantage. Conclusion: About half of new oxycodone use in NSW was preceded by a recent episode of hospital care or a therapeutic procedure. Higher rates of oxycodone initiation in rural and regional areas were not explained by sociodemographic factors.
AB - Aims: Oxycodone is the most commonly prescribed strong opioid in Australia. This study describes health service antecedents and sociodemographic factors associated with oxycodone initiation. Methods: Population-based new user cohort study linking medicine dispensings, hospitalizations, emergency department visits, medical services and cancer notifications from New South Wales (NSW) for 2014–2018. New users had no dispensings of any opioid in the preceding year. We analysed health service use in the 5 days preceding initiation and proportion of people on treatment over 1 year and fitted an area-based, multivariable initiation model with sociodemographic covariates. Results: Oxycodone accounted for 30% of opioid initiations. Annually, 3% of the NSW population initiated oxycodone, and 5–6% were prevalent users; the new user cohort comprised 830 963 people. Discharge from hospital (39.3%), therapeutic procedures (21.4%) and emergency department visits (19.7%) were common; a hospital admission for injury (6.0%) or a past-year history of cancer (7.2%) were less common. At 1 year after initiation, 4.6% of people were using oxycodone. In the multivariable model, new use of oxycodone increased with age and was higher for people outside major cities, for example, an incidence rate ratio of 1.43 (95% confidence interval 1.36–1.51) for inner regional areas relative to major cities; there was no evidence of variation in rates of new use by social disadvantage. Conclusion: About half of new oxycodone use in NSW was preceded by a recent episode of hospital care or a therapeutic procedure. Higher rates of oxycodone initiation in rural and regional areas were not explained by sociodemographic factors.
KW - opioids
KW - oxycodone
KW - pharmacoepidemiology
KW - small-area analysis
UR - http://www.scopus.com/inward/record.url?scp=85189946049&partnerID=8YFLogxK
UR - http://purl.org/au-research/grants/NHMRC/1138442
UR - http://purl.org/au-research/grants/NHMRC/1196900
U2 - 10.1111/bcp.16063
DO - 10.1111/bcp.16063
M3 - Article
C2 - 38571341
AN - SCOPUS:85189946049
SN - 0306-5251
VL - 90
SP - 1656
EP - 1666
JO - British Journal of Clinical Pharmacology
JF - British Journal of Clinical Pharmacology
IS - 7
ER -